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Pennsylvania, USAc; Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasadena, California USAd; Howard Hughes Medical Institute,
California Institute of Technology, Pasadena, California, USAe
The phosphorylation state of pocket proteins during the cell cycle is determined at least in part by an equilibrium between in-
ducible cyclin-dependent kinases (CDKs) and serine/threonine protein phosphatase 2A (PP2A). Two trimeric holoenzymes con-
sisting of the core PP2A catalytic/scaffold dimer and either the B55 or PR70 regulatory subunit have been implicated in the
activation of p107/p130 and pRB, respectively. While the phosphorylation state of p107 is very sensitive to forced changes of
B55 levels in human cell lines, regulation of p107 in response to physiological modulation of PP2A/B55 has not been eluci-
dated. Here we show that fibroblast growth factor 1 (FGF1), which induces maturation and cell cycle exit in chondrocytes, trig-
gers rapid accumulation of p107-PP2A/B55 complexes coinciding with p107 dephosphorylation. Reciprocal solution-based
mass spectrometric analysis identified the PP2A/B55 complex as a major component in p107 complexes, which also contain
E2F/DPs, DREAM subunits, and/or cyclin/CDK complexes. Of note, p107 is one of the preferred partners of B55, which also
associates with pRB in RCS cells. FGF1-induced dephosphorylation of p107 results in its rapid accumulation in the nucleus and
formation of larger complexes containing p107 and enhances its interaction with E2F4 and other p107 partners. Consistent with
a key role of B55 in the rapid activation of p107 in chondrocytes, limited ectopic expression of B55 results in marked dephos-
phorylation of p107 while B55 knockdown results in hyperphosphorylation. More importantly, knockdown of B55 dramati-
cally delays FGF1-induced dephosphorylation of p107 and slows down cell cycle exit. Moreover, dephosphorylation of p107 in
response to FGF1 treatment results in early recruitment of p107 to theMYC promoter, an FGF1/E2F-regulated gene. Our results
suggest a model in which FGF1mediates rapid dephosphorylation and activation of p107 independently of the CDK activities
that maintain p130 and pRB hyperphosphorylation for several hours after p107 dephosphorylation in maturing chondrocytes.
The retinoblastoma family of proteins, also called pocket pro-teins, consists of the product of the retinoblastoma tumor sus-
ceptibility gene and the functionally and structurally related pro-
teins p107 and p130. In their active, hypophosphorylated form,
these proteins associate with a variety of transcription factors and
chromatin-modifying enzymes negatively regulating cell cycle
progression and/or inducing differentiation (1–3). In cycling cells,
pocket proteins are hypophosphorylated in early to mid-G1 and
become hyperphosphorylated in response to mitogenic activation
of G1 cyclin/cyclin-dependent kinase (CDK) complexes coincid-
ing with passage through the restriction point. Mitogens stimulate
the expression of D-type cyclins and the downregulation of p27,
resulting in the sequential activation of D-type cyclin/CDK4/6
and cyclin E/CDK2 complexes that cooperate to phosphorylate
pocket proteins at multiple pro-directed Ser/Thr residues (3–5).
These phosphorylation events disrupt interactions with other
proteins and modulate intramolecular domain interactions and
access to docking sites for other protein regulators (1). One major
consequence of pocket protein inactivation is the disruption of
pocket protein/E2F4 repressor complexes, which results in dere-
pression of E2F-dependent genes, including those encoding G1/S,
S, and M cyclins as well as activator E2Fs, as cells commit to a new
round of DNA replication (3, 6). Although G1 and G1/S CDKs
become inactivated as cells progress through S phase in a cell-type-
dependent manner, the activation of the E2F program, the stabi-
lization of S-M cyclins, and phosphorylation/dephosphorylation
events targeting CDKs result in the sequential activation of cyclin
A/CDK2 and cyclin B/CDK1 complexes that maintain pocket pro-
teins hyperphosphorylated through the remainder of the cell cycle
until late mitosis (7–10), when the three pocket proteins are
abruptly and coordinately dephosphorylated (11, 12).
While a quite detailed picture of CDK-dependent phosphory-
lation and its consequences has been built in the past several years
(1, 10), the signals and the major players that mediate dephos-
phorylation and activation of pocket proteins remain poorly un-
derstood. Two major classes of Ser/Thr phosphatases, protein
phosphatase 1 (PP1) and PP2A, have been implicated in dephos-
phorylation of pocket proteins (4, 13). PP1 mediates, at least in
part, the dephosphorylation of pRB coinciding with abrupt inac-
tivation of CDK activity in late mitosis through mid-G1 (14). Dur-
ing this cell cycle window, PP1 is found to be associated with pRB
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(15), and recent detailed structural studies have shown that PP1
and CDKs compete for overlapping docking sites present in the C
terminus of pRB that are not conserved in p130/p107. In addition,
while p130 and p107 exhibit cyclin/CDK binding sites in the
spacer region that separates the conserved A and B domains of the
pocket region, these motifs do not bind PP1 (16). On the other
hand, we have found that sudden inactivation of CDKs in expo-
nentially growing human cell lines results in rapid, concomitant
dephosphorylation of the three pocket proteins (17). This dephos-
phorylation is mediated by PP2A, as it is inhibited by okadaic acid
at concentrations that do not inhibit PP1. Furthermore, it is in-
hibited by the expression of simian virus 40 small t antigen, and
both p130 and p107 associate with the catalytic subunit of PP2A.
This led to our proposal that the phosphorylation state of pocket
proteins is maintained by a dynamic equilibrium between PP2A
and CDKs throughout the cell cycle (17).
Although the importance of PP2A activity in modulating the
phosphorylation state of pocket proteins during the cell cycle was
clear, the identity of the particular PP2A holoenzyme implicated
was discovered more recently. PP2A forms trimeric holoenzymes
that contain a catalytic (C) and scaffold (A) core dimer that ap-
pears to be directed to different substrates by a regulatory B sub-
unit (18). There are two genes encoding two highly similar forms
of PP2A/C and PP2A/A and four different families of B subunits,
each with multiple members designated B, B=, B==, and B=== (4, 19).
The combination of these subunits into trimeric holoenzymes and
with additional subunits results in a myriad of different com-
plexes. For instance, proteomic analysis has identified an excess of
200 distinct PP2A complexes in cells (18). We have recently iden-
tified B55 as a regulatory B subunit of PP2A that directs p107 and
p130 to the PP2A holoenzyme in human cell lines (20). Indeed,
B55 remains bound to p107 even when excess small t antigen is
expressed in cells, which displaces multiple B subunits from the
PP2A core dimer. Loss- and gain-of-function assays demon-
strated that the phosphorylation state of p107 is extremely sensi-
tive to limited changes in the expression of B55. In these assays,
p130 appeared less sensitive while pRB appeared unchanged. We
reasoned that these differences were likely due to redundancy with
other PP2A holoenzymes that preferentially target pRB and p130.
Indeed, we found that PR70 preferentially bound pRB and p130
compared to p107 in in vitro pulldown assays. Altogether, this
suggested that, as is the case with CDKs, multiple PP2A holoen-
zymes may be specialized in mediating dephosphorylation of
pocket proteins during the cell cycle or in response to specific
cellular cues (20). Indeed, PR70 was found to target pRB for de-
phosphorylation in response to oxidative stress in a calcium-de-
pendent manner (21).
A question that remained unanswered was whether PP2A plays
mostly a non-rate-limiting role in the equilibrium with inducible
CDKs or whether cellular cues can trigger rapid activation of
pocket proteins without altering CDK activity through potent ac-
tivation of PP2A. A few previous reports had described PP2A-
mediated dephosphorylation of p107 or p130 in response to UV
(22), retinoic acid (23), and fibroblast growth factor 1 (FGF1) (24,
25), although the particular PP2A holoenzymes had not been de-
fined. Importantly, it has been shown that p107/ p130/ mice
exhibit defects in chondrocyte cell cycle exit that impair normal
endochondral bone formation (26). Given the critical physiolog-
ical relevance of p107 activation for chondrocyte cell cycle exit and
maturation revealed by ablation of p107/p130 in mice, this study
is focused on identification of the PP2A holoenzyme induced by
FGF1 in chondrocytes. FGF1 induces rapid dephosphorylation of
p107 in rat chondrosarcoma (RCS) cells by a mechanism that is
associated with complex formation with PP2A, as knockdown of
PP2A/A or PP2A/C inhibits p107 dephosphorylation and chon-
drocyte cell cycle exit (25). Since FGF signaling is critical for en-
dochondral bone formation, as defects in the FGFR3 result in
achondroplasia (27), we sought to characterize the trimeric ho-
loenzyme inducible by FGF and the consequences of targeting
p107 during chondrocyte maturation and cell cycle exit. Using
RCS cells, we identify PP2A/B55 as the critical holoenzyme tar-
geted to p107 following FGF1 stimulation, which results in gener-
ation of larger complexes containing p107 as well as changes in
p107 complexes. In concert with activation of p107, we found
recruitment of p107 to the E2F-regulated promoter of the MYC
gene, which has been found to have downregulated expression
during this process. In addition, using proteomics analysis, we
found that members of the B family (primarily B55 and to a
lesser extent B55) are the only B subunits detected in association
with p107 in these cells and thus mediate recruitment of the PP2A
core dimer. This is also consistent with cooperation of B55 and
55 small interfering RNAs (siRNAs) in inhibiting p107 dephos-
phorylation. Of note, p107 complexes containing CDKs and/or
PP2A exist in cells at comparable relative levels, a finding which
suggests a critical competitive equilibrium between these com-
plexes which is apparently disturbed by FGF signaling.
MATERIALS AND METHODS
Cell culture and cell treatments. RCS cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Cellgro) supplemented with 9% fetal
bovine serum (FBS) (Atlanta Biologicals), 100 U/ml penicillin, and 100
g/ml streptomycin (Gemini) at 37°C in a humidified atmosphere with
9% CO2. Fibroblast growth factor 1 (Peprotech) was reconstituted in 5
mM Na2(HPO4), pH 8.0, and 0.1% bovine serum albumin (BSA) at a
concentration of 5 g/ml. RCS cells were treated at indicated time points
at a final FGF concentration of 5 ng/ml culture medium plus 5 g/ml
heparin (Calbiochem). Primary chondrocyte cultures were prepared from
metatarsal rudiments isolated from Sprague-Dawley rat fetuses at 20 days
postcoitus (dpc) as previously described (28) and maintained in complete
DMEM supplemented with 50 g/ml ascorbic acid.
Flow cytometric cell cycle analysis. RCS cells were collected at the
indicated time points and fixed in methanol. Prior to analysis, the cells
were treated with a solution containing 10% propidium iodide (500 g/
ml), 5 mg/ml 10% RNase A and 80% 1 phosphate-buffered saline (PBS)
plus 1% FBS, and incubated at 37°C for 30 min. The cells were analyzed
with a FACSCalibur (BD) flow cytometer, and the data were analyzed
using Cell Quest software (BD).
Protein expression and analysis. All protein assays were conducted
on ice or at 4°C unless otherwise indicated. Protein extracts were prepared
by lysing cells in RCS buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 10 mM
KCl, 1 mM EDTA, 1% NP-40, 50 mM NaF, 1 mM Na3VO4, 10 mM
sodium pyrophosphate, 10 mM -glycerophosphate, 1 mM phenylmeth-
ylsulfonyl fluoride [PMSF], 10 g/ml leupeptin, 4 g/ml pepstatin, 4
g/ml aprotinin) for 30 min and cleared by centrifugation. Western blot
analysis and immunoprecipitations were performed as previously de-
scribed (17). Proteins were resolved by SDS-PAGE, in which 6% gels were
used to determine the phosphorylation status of pocket proteins and 8%
to 12% gels were used to assess protein expression. For immunoprecipi-
tation of endogenous proteins, we used 1 mg of precleared whole pro-
tein lysate per antibody. Lysates were precleared using normal mouse or
rabbit IgG and incubated overnight while rocking with specific antibodies
and protein A or G beads. Following incubation, the beads were washed 4
to 5 times with RCS buffer. Immunoprecipitates were resolved by SDS-
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PAGE and analyzed via Western blotting. Subcellular localization studies
were performed utilizing the NE-PER nuclear and cytoplasmic extraction
kit (Thermo Scientific) according to the manufacturer’s directions.
Antibodies.Anti-p107 (sc-318), anti-cyclin A (sc-596), anti-E2F4 (sc-
512), anti-p21 (sc-397), anti-CDK2 (sc-163), and anti-CDK4 (sc-601)
rabbit polyclonal antibodies, anti-PP2A/A (sc-6113) and anti-COL2A1
(sc-7764) goat polyclonal antibodies, anti-PP2A-B55 (sc-81606) and
anti-cyclin E (sc-248) mouse monoclonal antibodies, and normal rabbit
(sc-2027) and normal mouse (sc-2025) IgG were purchased from Santa
Cruz Biotechnology. The anti-PP2A-B55 (100C1) rabbit monoclonal
and anti--actin (4967) rabbit polyclonal antibodies were purchased
from Cell Signaling Technology. Anti-p130 (R27020), anti-PP2A/C
(1D6), anti-pRB (G3-245), and anti-HSP70 (ADI-SPA-822) monoclonal
antibodies were purchased from BD Transduction Laboratories, Upstate
Biotech, Millipore, BD Pharmingen, and Enzo Life Sciences, respectively.
The anti-PP2A-B55 (GTX116609) antibody was purchased from Gene-
Tex, and anti-CTCF (ab70303) was purchased from Abcam.
Plasmids and siRNA. pSG5-puro-Flag-p107 was made by excising the
Flag-p107 construct from pCMV-Flag-p107 (20) and inserting it into the
pSG5-puro vector. pMSCV-Myc-B55 wild type (WT) and pMSCV-
Myc-B55 D197K were described previously (20). pLKO.1 short hairpin
RNA (shRNA) Ppp2r2a and scramble plasmids were purchased as a set in
bacterial glycerol stock from Sigma (Mission shRNA; SCHLNG-NM_
028032). TRCN0000241288 and TRCN0000241290 were used in the
shRNA knockdown experiments and renamed shRNA 1 and 2, respec-
tively. Ppp2r2a siRNAs were purchased from Dharmacon, and their se-
quences are as follows: siRNA 1, 5=-UGACUGGAUCCUACAAUAAUU-
3=; siRNA 2, 5=-CAGCAGAUGAUUUGCGAAUUA-3=; siRNA 3, 5=-CAG
UAGAGUUUAAUCAUUC-3=. siGENOME nontargeting siRNA pool 2
(D-001206-14) was used as the control. For subcellular localization and
cell cycle experiments, Ppp2r2a siRNAs 2 and 3 were used together along
with 1 Ppp2r2d siRNA, 5=-GAGACUAUCUGUCGGUGAA-3=. For the
rescue experiment, Ppp2r2a siRNAs 2 and 3 were used for open reading
frame (ORF) knockdown, while the following 2 siRNAs against the 3=
untranslated region (UTR) were used for UTR knockdown: UTR1, 5=-C
CAUGUCUGCUAGCCAUUU-3=; UTR2, 5=-UUGUCUCGGUGGUGG
CGUAUU-3=.
Lentiviral infections and transfections. 293T cells were transfected
with the pLKO.1 vectors and pCMV-R 8.2 and pCMV-VSVg packaging
constructs at a 2:1.3:1g DNA ratio, respectively, using the calcium phos-
phate method. Supernatants were collected 48 h posttransfection and
added to the RCS cells, which were selected with medium containing 2
g/ml puromycin 24 h after infection. For protein expression, all RCS cell
transfections were performed using the Fugene HD reagent (Promega) at
an 8:1 ratio. siRNA transfections were performed using 37.5 nM siRNA
duplex and the reverse transfection protocol with Lipofectamine RNAi
Max reagent (Life Technologies) according to the manufacturer’s instruc-
tions. A total of 9 105 cells/10-cm plate or 3 105 cells/6-mm plate were
transfected twice, 24 h apart, and allowed to grow for 48 to 72 h posttrans-
fection prior to treatment.
Proteomics. RCS-Flag-p107 and RCS-Myc-B55WT stable cell lines
were made by stably expressing pSG5-puro-Flag-p107 and pMSCV-Myc-
B55 WT in RCS cells and selecting with 2 g/ml puromycin. Colonies
expressing levels of tagged protein similar to those of the corresponding
endogenous protein were selected for these experiments. About 15 to 20
15-cm plates of exponentially growing cells were collected (4 to 7 mg of
protein) and lysed in a buffer containing 50 mM HEPES, pH 7.5, 70 mM
potassium acetate [K(OAc)], 5 mM magnesium acetate [Mg(OAc)2],
0.2% maltoside (Thermo Scientific), and a protease inhibitor tablet
(Roche). Cell lysates were immunoprecipitated with anti-Flag M2 affinity
gel (A2220; Sigma) or anti-Myc affinity gel (A7470; Sigma). The beads
were subsequently washed 5 times in lysis buffer and 2 times in MS buffer
(0.1 M Tris-HCl; pH 8.5), and the peptides were eluted with saturated
urea, treated with Tris(2-carboxyethyl)phosphine (TCEP) (Sigma) and
2-chloracetamide (Sigma), and digested sequentially with endoproteinase
Lys-C (Wako) and trypsin (Promega). Liquid chromatography-mass
spectrometry experiments were carried out on an EASY-nLC connected
to a hybrid LTQ-Orbitrap Classic equipped with a nanoelectrospray ion
source (Thermo Scientific). Mass spectrometry spectra were analyzed us-
ing Mascot 2.2.0 (Matrix Science) and Scaffold 3 (Proteome Software,
Inc.) against human databases essentially as described in reference 29.The
resulting false-discovery rate was less than 1%.
FPLC. RCS cells were treated with FGF at the indicated time points,
lysed, and filtered through a 0.22-m spin column. A total of 600 g of
protein was loaded onto a Superdex 200 10/300 GL column (GE Health-
care) and separated on an AKTA fast protein liquid chromatographer
(FPLC) (GE Healthcare) at a flow rate of 0.50 ml/minute and collected in
0.5-ml fractions. The FPLC buffer was filtered and degassed RCS buffer. A
total of 40l of each protein-containing fraction was resolved using SDS-
PAGE and analyzed by Western blotting.
ChIP. Chromatin immunoprecipitation (ChIP) experiments were
carried out essentially as described previously (30, 31). RCS cells (0.5 
106) were seeded in 15-cm plates, cultured for 36 h, and treated with
FGF1-heparin or heparin as indicated above. Treated cells were fixed with
1% formaldehyde-PBS for 15 min at room temperature, and the cross-
linking reaction was stopped by adding glycine (0.125 M). Cells were then
washed twice with cold PBS and harvested with complete Szak’s radioim-
munoassay (RIPA) buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxy-
cholate, 0.1% SDS, 50 mM Tris-HCl [pH 8], 5 mM EDTA, protease in-
hibitor cocktail [Roche], 10 mM PMSF). Cells were then sonicated for 10
cycles of 30 s on and 30 s off (amplitude set at 70) in an ice bath using a
Fisher Scientific Model 705 Sonic Dismembrator. Sonicated chromatin
was cleared by centrifugation. The protein concentration was quantified
by using the bicinchoninic acid (BCA) protein assay kit (Thermo Scien-
tific). Sonicated DNA was about 300 bp. Subsequent steps were per-
formed as described previously (31). After DNA precipitation, the pellet
was resuspended in water and analyzed by quantitated PCR (qPCR).
SYBR green qPCR mix (Fermentas) was used to determine relative DNA
amounts in input chromatin samples and ChIPs (anti-p107, anti-p130,
anti-E2F4, and IP mock [IgG]) in 96-well plates using the StepOnePlus
PCR instrument (Applied Biosystems). Specific and mock ChIP threshold
cycle (CT) values were normalized with input CT values to obtain the
percentage of input values separately for each primer set. The percentage
of input was calculated, mock ChIP values were subtracted from p107,
p130, or E2F4 ChIP values, and results were visualized via Excel graphs.
The following antibodies were used for ChIP: anti-p107 (sc-318), anti-
E2F4 (sc-1082), and mouse monoclonal IgGs (sc-2025) from Santa Cruz
Biotechnology and anti-p130 (R27020) from BD Transduction Laborato-
ries. Reference Sequences (RefSeq) for the rat promoters assayed by ChIP
were obtained from the ECR browser (http://ecrbrowser.dcode.org).
Primer pairs were designed using Oligo Perfect Designer (www.invitrogen
.com) to amplify sequences near E2F elements conserved between rats and
humans and/or mice. Primer sequences are as follows: for MYC, GGATC
CGGAGTCGCAGTAT and CAAAGCCCTTCTCACTCCAG; for E2F3,
GCGTAAACCGTATCCCTTCA and AAAAATAATCGGGGGTCTGG;
forCDC6, GTGGGTGTGACTTCGTGTTG and GGAGCTTTGCACTCT
TCAGG; and for FGFR1, GTGTGCCTTGGGGTATGATT and CGGAG
TGAACCACAAAACCT.
RESULTS
A model of chondrocyte maturation and cell cycle exit in response
to treatment with FGFR3 ligands has been extensively character-
ized (32, 33). RCS cells undergo cell cycle arrest upon treatment
with FGF1 (32–35). As shown in Fig. 1A, RCS cells were treated
with FGF1 plus heparin or heparin alone at the indicated time
points, collected, stained with propidium iodide, and subjected to
fluorescence-activated cell sorter (FACS) analysis. A transient ac-
cumulation of cells with G2/M DNA content is observed early and
subsequently is reduced as cells accumulate with G0/G1 DNA con-
tent. The transient arrest at the G2/M transition has previously
Kurimchak et al.
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been shown to be caused by the transient inactivation of cyclin
B1/CDK1 complexes following FGF1 stimulation (36). Note that
heparin control-treated cells show a much smaller increase in the
percentage of cells with G0/G1 DNA content but that the cells
continue to proliferate and do not exit the cell cycle. Western blot
analysis of lysates of FGF1-treated cells also confirmed the rapid
dephosphorylation of p107 1 h after FGF1 treatment, which pre-
cedes pRB and p130 dephosphorylation by several hours (Fig. 1B)
(24). As we have previously shown that B55, a PP2A regulatory
subunit belonging to the B family, modulates the phosphorylation
state of p107 in human cells and that p107 phosphorylation is very
sensitive to forced changes in B55 expression, we determined
B55 protein levels during the time course (Fig. 1B). B55 protein
levels are unaffected by FGF1 treatment, while collagen II, a
marker of immature or undifferentiated chondrocytes, gradually
decreases. Interestingly, an increase in p21 expression is observed
around 10 to 15 h after treatment, coinciding with dephosphory-
lation of pRB and accumulation of hypophosphorylated p130.
The upregulation of p21 in response to FGF1 stimulation in these
cells has been reported earlier and coincides with inactivation of
cyclin E/CDK2 complexes and pRB hypophosphorylation (34).
Since the CDK4/6 inhibitor p16 is also upregulated in response to
FGF treatment in these cells (24), dephosphorylation of pRB and
p130 is likely a consequence of inhibition of CDK2 and CDK4
while dephosphorylation of p107 is compatible with upregulation
of PP2A activity toward p107 as previously reported (25).
Kolupaeva et al. reported that FGF1 induces transient forma-
tion of p107-PP2A/A-PP2A/C complexes in response to FGF1
treatment (25). In this setting, expression of adenovirus E4orf4,
which targets primarily subunits of the B55 family (37), blocked
FGF-mediated dephosphorylation of p107 (25). While we did not
observe modulation of B55 levels by FGF1, it was still conceiv-
able that FGF1 induces complex formation between the PP2A/
B55 holoenzyme and p107 via some other mechanism. First, we
determined if these complexes are detected in untreated RCS cells,
as we have previously detected low levels of these complexes in
U2-OS cells. Reciprocal immunoprecipitations with antibodies to
p107 and B55 demonstrate the interaction between endogenous
p107 and the three subunits of the PP2A/B55 holoenzyme in
untreated cells (Fig. 2A). Given that p107 is rapidly dephosphor-
ylated in RCS cells following FGF1 treatment, we next wanted to
determine if this signal recruits additional PP2A/B55 holoen-
zymes to p107. RCS cells were treated with FGF for 30 min (we
observe dephosphorylation of p107 as soon as 15 min posttreat-
ment; data not shown), lysed, and immunoprecipitated with p107
antibodies. We detected a marked increase in the association of
the three subunits of the PP2A/B55 holoenzyme with p107 with-
out changes in the expression of p107 or the subunits of the B55/
PP2A holoenzyme (Fig. 2B). This upregulation is transient, as it is
not maintained at longer time points (data not shown). These data
suggest that FGF1 induces formation of a PP2A/B55-p107 com-
plex via posttranslational modification(s) on any of the subunits
involved or the participation of an additional factor regulated by
FGF1. We also determined the effects of FGF1 in primary rat
chondrocytes obtained as described in Materials and Methods.
Treatment of these cells with FGF1 promotes cell cycle arrest at 24
h poststimulation (Fig. 2C). p107 dephosphorylation is clearly
detected 2 h poststimulation yet is not as complete as seen in RCS
cells, likely due to the unavoidable heterogeneity of the primary
cells (compare Fig. 2C, left panel, to Fig. 1B). Immunoprecipita-
tion of endogenous p107 from lysates of FGF1-treated rat chon-
drocytes with specific antibodies resulted in detection of a B55/
p107 complex, which peaked 2 h poststimulation (Fig. 2D). Thus,
the p107/B55 interaction is detectable in a rat cell line and in
primary rat chondrocytes, and it is inducible by FGF1.
To determine if B55 was the primary B regulatory subunit
targeting the PP2A/A-C dimer to p107, we generated RCS cell
lines ectopically expressing Myc-tagged B55 and Flag-tagged
p107. Myc-B55 was expressed at about 75% of the level of the
endogenous protein (Fig. 3A, clone 3), while Flag-p107 was ex-
pressed at around120% of the level of endogenous p107, and its
phosphorylation state is modulated by FGF1 (Fig. 3B, clone 6).
Both cell lines grew efficiently and maintained the transgene sta-
bly. We next performed immunoprecipitations from lysates of
about 2.25  107 cells using antibodies against each tag. Immu-
noprecipitates were extensively washed, and tryptic peptides were
subjected to liquid chromatography-tandem mass spectrometry
(LC-MS/MS) analysis. As shown in Fig. 3C, the Flag-p107 pro-
teomics analysis yielded peptides that allowed identification of
FIG 1 FGF1 induces rapid p107 dephosphorylation prior to pRB dephos-
phorylation, p130 accumulation, and subsequent G1 arrest and maturation in
RCS cells without changes in the expression of B55. RCS cells were stimulated
with FGF1 in the presence of heparin or with heparin alone (control). Cells
were collected at the indicated times for cell cycle FACS analysis (A) and West-
ern blot (B). Hyper- and hypophosphorylated forms of p107/p130/pRB and
maturation markers are indicated. The asterisk indicates a cross-reacting band.
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multiple known partners of p107, including E2F/DP1 transcrip-
tion factors, cyclins and CDKs, multiple subunits of the DREAM
complex (LIN proteins) (38), and a number of peptides corre-
sponding to proteins not previously found as partners of p107
(Mybbp1a, p400, and Herc2). Importantly, we detected peptides
corresponding to the catalytic B subunit, scaffold, and two mem-
bers of the B family of regulatory PP2A subunits (B55 and B55).
Based on the number of spectral hits, B55 is the preferred B
subunit partner of p107, with B55 being significantly less abun-
dant (one peptide unique to B55 and two peptides common to
B55 and B55). Of note, no other PP2A/B subunits or subunits
of any other phosphatase were detected in the proteomic analysis,
suggesting a major role of B55 in modulation of p107 in chon-
drocytes. In striking agreement with these results, Fig. 3D shows
that one of the major partners of the PP2A/B55 holoenzyme in
these cells is p107, which was ranked as the 4th most abundant
partner of B55 other than PP2A subunits by number of spectral
hits. Interestingly, we also detected several peptides correspond-
ing to pRB, suggesting that pRB is also a substrate of this holoen-
zyme (see Discussion). To confirm these results, we performed
immunoprecipitations using Flag-p107 cells and were able to ver-
ify many of the binding partners with more spectral hits, including
cyclins A and E, CDK2, and CDK4 (Fig. 3E) and PP2A subunits
(data not shown). Due to the high sensitivity of the LC-MS/MS
and the unavailability of adequate antibodies for detection of en-
dogenous interactions, some of the minor partners have yet to be
FIG 2 (A) Endogenous PP2A/B55 complexes coimmunoprecipitate with p107 in chondrocytes, and the association is markedly increased upon FGF1
treatment in RCS cells. Whole-cell lysates were immunoprecipitated with the indicated antibodies and resolved by Western blot analysis with antibodies to the
indicated proteins (A, B, and C). (B) FGF1 induces rapid transient formation of p107/B55 PP2A complexes coinciding with p107 dephosphorylation in RCS
cells. RCS cells were stimulated with FGF1 in the presence of heparin for 30 min. (C) FGF1 induces p107 dephosphorylation and growth arrest in primary rat
chondrocytes. Primary rat chondrocytes were treated with FGF1 (20 ng/ml) and heparin or heparin alone, and cells were processed as described for Fig. 1A (left)
or for Western blot analysis (right). (D) B55 coimmunoprecipitates with p107 in primary rat chondrocytes.
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confirmed via immunoprecipitation followed by Western blot
analysis.
We previously demonstrated that limited ectopic expression of
B55 in U2-OS cells results in accumulation of hypophosphory-
lated p107, and this is not observed with a D197K point mutant
that fails to bind p107 (20). To determine whether limited expres-
sion of B55 in RCS cells induces p107 dephosphorylation, RCS
cells were transfected with Myc-B55-WT, Myc-B55-D197K, or
an empty vector. Figure 4A shows that limited expression of
B55-WT results in marked accumulation of hypophosphory-
FIG 3 Generation of stable RCS-Flag-p107 and RCS-Myc-B55 cell lines and analysis of Myc-B55 and Flag-p107 complexes in RCS cells via solution-based
proteomics analysis. Stable RCS-Myc-B55 and RCS-Flag-p107 clones were generated as described in Materials and Methods (A and B). (A) RCS-Myc-B55
clone 3 was selected for proteomics analysis. Vec, vector. (B) Clone 6 was selected for proteomics analysis. Note that the hypophosphorylated form of Flag-p107
(F-hypo) comigrates with endogenous hyperphosphorylated p107 (hyper) (differentially phosphorylated forms are indicated). (C and D) RCS-Flag-p107
(F-p107), RCS-Myc-B55 (M-B55), and control RCS-vector (Vec-Ct) cells were lysed, and p107 and B55 complexes were immunoprecipitated with
corresponding antitag antibodies and processed for proteomics analysis as described in Materials and Methods. Numbers indicate the numbers of spectral hits
and are ranked. (C) Proteins are grouped based on function as E2F/DP, LIN members of DREAM complex, cyclin/CDKs, and B55-PP2A holoenzymes. The last
group (green) contains potential unvalidated novel interactions. (D) B55 holoenzyme and potential substrates are indicated on the right. A few spectral hits
were also detected for two LIN proteins, a cyclin, and a CDK and are indicated on the right but not shown in this truncated table. If confirmed, these proteins may
be associated with p107 or forming independent complexes with B55. The plus sign indicates confirmation by IP/Western blot (WB) analysis. (E) Confirmation
of select binding partners from proteomics analysis. RCS Flag-p107 cells were treated with FGF1 for 2 h, collected, immunoprecipitated using the M2 Flag
antibody, and subjected to WB analysis. Cont., the parental RCS line.
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lated p107, which does not occur in the cells expressing the empty
vector or the Myc-B55-D197K mutant. Conversely, cells trans-
fected with two different B55 siRNAs exhibit increased levels of
hyperphosphorylated p107 relative to the untransfected and
scramble siRNA controls (Fig. 4B), demonstrating that relative
small changes in the expression of B55 protein markedly affect
p107 phosphorylation in RCS cells. To determine whether B55 is
important for FGF1-mediated dephosphorylation of p107, we
used two different shRNAs alone or in combination to knock
down B55 and subsequently treated the virally transduced cells
with FGF1 for 30 min or 2 h. We have noticed that shRNA knock-
down of B55 in these cells is not very efficient. Nevertheless,
knockdown of B55 by 50% markedly delays FGF1-induced
p107 dephosphorylation (Fig. 4C). At 30 min, p107 dephosphor-
ylation is mostly complete in the FGF1-treated shRNA vector con-
trol cells but not in the cells with B55 knockdown. This delay is
still clearly detected by 2 h of FGF1 treatment. Subsequently, we
used multiple siRNAs and double reverse transfection that re-
sulted in more-effective knockdown of B55 and delayed, but not
completely blocked, FGF1-induced dephosphorylation (Fig. 4D
and E). It is possible that complete and/or more-sustained knock-
down of B55 is required to fully block FGF1-induced dephos-
FIG 4 The phosphorylation state of p107 is sensitive to changes in the expression of B55, and loss of B55 function delays p107 dephosphorylation in response
to FGF signaling RCS cells. (A) Overexpression of B55 results in a relative accumulation of hypophosphorylated p107, which is not observed with a D197K point
mutant (Mut). Vec, vector; WT, wild type. (B) siRNA-mediated knockdown of B55 results in a relative increase of hyperphosphorylated p107 not seen in cells
transfected with scrambled (Sc) siRNA. NT, not transfected. (C) RCS cells were transduced with lentiviruses encoding B55 or control shRNA vectors, selected
with puromycin for 3 days, and then stimulated with heparin alone (FGF) or FGF and heparin (	FGF) for the times indicated. Proteins were detected via WB
analysis. V, vector. (D) siRNA-mediated knockdowns of B55 and B55 cooperate to prevent FGF1-induced p107 dephosphorylation (right). Levels of B55 and
B55 are shown on the right. Scr, scrambled. (E) Expression of B55 resistant to siB55 directed to the UTR promotes p107 dephosphorylation even in the
presence of B55UTR siRNA. p107 hypophosphorylated (white bullets) and hyperphosphorylated (black bullets) forms are indicated. ORF, open reading frame;
UTR, untranslated region.
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phorylation of p107. However, since B55 is likely a minor partner
of p107 (Fig. 3C), it is also conceivable that B55 compensates in a
setting in which B55 expression is reduced. Figure 4D shows that
although B55 siRNAs had little effect on p107 dephosphoryla-
tion, B55/B55 double knockdowns were more effective at de-
laying p107 dephosphorylation than the B55 knockdown. More-
over, we also determined if the delays in FGF1-dependent p107
dephosphorylation resulting from siRNAs targeting either the
ORF or the UTR of B55 can be attenuated by limited expression
of a B55 transgene lacking its natural UTR. As expected (Fig. 4E,
lower panel), expression of exogenous B55 resulted in more-
effective dephosphorylation of p107 and effectively prevented a
dephosphorylation delay by the siRNAs targeting the UTR, a re-
sult which is clearly seen in the upper panel. However, the siRNA
targeting the ORF can still prevent complete dephosphorylation of
p107. Considering (i) that multiple different shRNAs and siRNAs
targeting B55 but not the vector/scramble controls promote
p107 hyperphosphorylation and delay FGF1-dependent p107 de-
phosphorylation and (ii) the observation that FGF1 induces rapid
formation of a B55/PP2A holoenzyme complex with p107 coincid-
ing with p107 dephosphorylation, we conclude that B55 is the ma-
jor modulator of the p107 phosphorylation state in RCS cells and the
key upstream activator of p107 in FGF signaling in chondrocytes.
Because FGF1 induces rapid dephosphorylation of p107 and
thus appears to generate active p107, we next determined if FGF1
changed the localization of p107. As shown in Fig. 5A, stimulation
of RCS cells with FGF1 leads to a rapid relative increase in the
localization of p107 to the nucleus by 1 h which is subsequently
downregulated as p130 levels accumulate in both the nuclear and
cytoplasmic fractions and cells exit the cell cycle. While cytoplas-
mic fractions consist of hyperphosphorylated and hypophosphor-
ylated p107, the nuclear fraction apparently contains only hypo-
phosphorylated p107. Of note, while knockdown of B55 and
B55/B55 clearly delayed FGF1-induced dephosphorylation in
the cytoplasmic fraction, it had only modest effects in the fraction
of p107 relocated to the nucleus (data not shown). This indicates
that either relocalization of p107 to the nucleus is not solely de-
pendent on p107 dephosphorylation or, alternatively, the level of
knockdown is insufficient to drastically affect p107 accumulation
in the nucleus.
Next we determined if FGF1 affected the mass of p107 com-
plexes. To this end, we fractionated lysates of cells treated with
FGF1 for 30 min and 2 h by FPLC/gel filtration. As seen in Fig. 5B,
FGF1 stimulation resulted in decreased detection of hyperphos-
phorylated p107 in fractions 19 and 20 (the smallest p107 com-
plexes) and a relative increase in the detection of p107 in larger
complexes with a peak in fractions of about 670 kDa after 30 min
and 2 h. The levels of p107 in each fraction relative to the level of
p107 in all fractions combined are shown graphically (Fig. 5B,
right), clearly showing the downregulation of the peak containing
hyperphosphorylated p107 in small complexes in FGF1-treated
cells. We also determined effects of FGF1 on E2F4 and found a
major change in the mobility of E2F4 isoforms as well as a relative
accumulation of E2F4 in the larger fractions. The changes in E2F4
isoform mobility may be due to posttranslational modifications.
No major changes were detected in the fractionation of Myb (Fig.
5A) or the subunits of the PP2A/B55 holoenzyme (data not
shown). To verify our FPLC data, we performed p107 IPs on RCS
cells treated with FGF1 for 15, 30, and 60 min. p107 dephosphor-
ylation is observed as early as 15 min after the addition of FGF1,
and this coincides with an increase in E2F4 association (Fig. 5B).
These data show that FGF1-mediated dephosphorylation of p107
results in remodeling of p107 complexes.
To ascertain the consequences of activation of p107, we deter-
mined if recruitment of p107 to promoters of E2F-regulated
genes, whose expression is often regulated by FGF1 (24), is mod-
ulated. First, we determined recruitment of p107, p130, and E2F4
to the promoters of various genes containing canonical E2F ele-
ments, including a subset of genes whose products are downregu-
lated by FGF, 24 h after FGF stimulation via chromatin immuno-
precipitation (ChIP) assays. RCS cells were treated in the presence
or absence of FGF1 for 24 h, and ChIP assays were performed as
described previously (31). Consistent with accumulation of active
hypophosphorylated p130 forms known to interact with E2F4
(Fig. 1) (39), we observed increased recruitment of both p130 and
E2F4 to the E2F3, CDC6, and CDK2 promoters (Fig. 6A and data
not shown). Of note, while p107 was clearly detected at these
promoters (Fig. 6A and data not shown), there was no modulation
of p107 occupancy by 24 h of FGF1 stimulation. Interestingly,
whileMYC expression is downregulated by FGF (24) and contains
an E2F element in its promoter, we observed little recruitment, if
any, of p107/p130 at this time point. As a control, we also deter-
mined occupancy at a region of the FGFR1 promoter that, al-
though it contains a consensus E2F sequence, is not known to be
functional. None of these factors were detected at this promoter
region. Since p107 is activated several hours prior to activation of
p130 (Fig. 1B), we next determined recruitment of p107 to the
same promoters 1.5 h after FGF stimulation via ChIP analysis.
Figure 6B shows that an increase in p107 promoter occupancy is
observed at the MYC promoter after 1.5 h of FGF treatment. p107
was also clearly detected at the E2F3 and CDC6 promoters, but
p107 occupancy increased only slightly at these promoters. These
data are consistent with an FGF1-stimulated repressive role for
p107 in the expression of MYC and perhaps other genes that are
downregulated early during chondrocyte maturation and the ini-
tiation of cell cycle exit. Also of note, while E2F4 is detected at the
MYC,E2F3, andCDC6promoters,E2F4 occupancy is not induced
early by FGF1, suggesting that p107 may regulate the MYC pro-
moter in cooperation with factors other than E2F4. De-cross-
linked lysates were analyzed by Western blot to monitor p107
dephosphorylation as a control (Fig. 6C).
Lastly, we wanted to determine if B55 and/or B55 is required
for FGF1-induced cell cycle exit in RCS cells. siRNAs to both B55
and B55 delay but do not block cell cycle exit. The effects are seen
early, as the reduction in the number of cells in S phase induced by
FGF1 is significantly slower in cells with reduced B55 and/or
B55 (8 h) (Fig. 7A). However, these effects are not additive, and
most cells appear to exit the cell cycle. In addition, we observe
more clear effects in the accumulation of cells with G2/M DNA
contents (Fig. 7B), a finding which is consistent with the recently
proposed role of these phosphatases in counteracting the action of
CDK1 in modulating the phosphorylation state of mitotic sub-
strates (4, 8, 40). Even when considering cells accumulating from
S phase to mitosis (Fig. 7C), it is clear that cells efficiently exit the
cell cycle by 22 h. It is likely that even in B55/B55 knockdown
cells, there is enough remaining PP2A activity to activate p107
when CDK activities are downregulated at later times by CKIs
coinciding with the activation of p130 and pRB.
Altogether, our data show that B55 is implicated in the rapid
and selective activation of p107 during chondrocyte maturation
FGF Activates p107 via the PP2A/B55 Holoenzyme
August 2013 Volume 33 Number 16 mcb.asm.org 3337
 o
n













and cell cycle exit. Active stimulation of B55/p107 complexes
mediates p107 dephosphorylation prior to inactivation of CDK ac-
tivity that reportedly occurs several hours later. The preferential as-
sociation of p107 with B55 compared to p130 and pRB (20) (Fig.
3D) likely determines the differential timing of activation of pocket
proteins during chondrocyte maturation and cell cycle exit (Fig. 8).
DISCUSSION
The data reported here support a model in which FGF1 promotes
assembly of PP2A/B55 holoenzymes with p107 by a mechanism
that does not involve upregulation of B55 protein levels (Fig. 8).
The relative increase in PP2A/B55 holoenzymes targeting p107
shifts the equilibrium with CDKs toward rapid and selective de-
phosphorylation and activation of p107 without affecting pRB
and p130, which remain hyperphosphorylated. Dephosphoryla-
tion of p107 results in its transient accumulation in the nucleus,
remodeling of complexes, including an increase in p107/E2F4 and
p107/cyclin/CDK complexes, and p107 targeting to theMYC pro-
moter, which is downregulated early in this process, as well as
potentially other cell cycle and/or maturation genes. Because p130
FIG 5 FGF1 induces changes in p107 localization and protein complexes. (A) RCS cells were treated with FGF1 and collected at the indicated time points.
Cytoplasmic and nuclear lysates were obtained and resolved by SDS-PAGE for Western blot analysis. The asterisk indicates a cross-reacting band. Hypo- and
hyperphosphorylated p107 forms are indicated. (B) Hypophosphorylated p107 elutes with larger complexes, and relative accumulation of these complexes is
stimulated by FGF1. Lysates of RCS cells stimulated with FGF1 at the indicated time points were analyzed via gel filtration FPLC followed by a Western blot with
p107 and E2F4 antibodies. (C) FGF1 induces rapid formation of p107/E2F4 complexes coinciding with p107 dephosphorylation in RCS cells. RCS cells were
stimulated with FGF1 in the presence of heparin for the indicated time points. Whole-cell lysates were immunoprecipitated with p107 antibodies and resolved
by Western blot analysis with antibodies to p107 and E2F4.
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and pRB remain hyperphosphorylated early on and, thus, inac-
tive, they do not seem to play an initiating role in controlling gene
expression during the very early steps of chondrocyte maturation
that culminate in cell cycle exit. Hours after activation of p107, the
CDK inhibitors p16 and p21 are upregulated (24, 34), and in the
case of p21, this coincides with cyclin E/CDK2 inactivation and
pRB dephosphorylation (34), which occurs in parallel with p130
dephosphorylation. This two-tier, sequential activation of pocket
proteins and the demonstrated requirement of p107/p130 for
chondrocyte cell cycle exit and endochondral bone formation (26,
41) are likely in place to coordinate repression of cell cycle genes
and perhaps induction of maturation genes (Fig. 8). Importantly,
the proposal that p107 and p130/pRB are activated by FGF
through separate pathways, B55 or CKI activation, respectively,
is consistent with the finding that simultaneous disruption of
p107 and p27 or p57 is analogous to disruption of p107 and p130
in chondrocyte cell cycle exit and endochondral bone formation
(26, 42, 43). In this regard, coablation of p107 and p27 in mice
strongly suggests that p27 and p130 act in analogous pathways
(43).
FIG 6 FGF1-regulated p107 occupancy at promoters containing canonical E2F elements. (A and B) RCS cells were stimulated with FGF1 and heparin or heparin
alone and fixed with formaldehyde 24 (A) or 1.5 (B) h later. ChIPs were performed as described in the experimental design section. (C) p107 dephosphorylation
was determined by a Western blot (as described above).
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An equilibrium between cell cycle-induced CDKs andmatu-
ration/differentiation-induced PP2A may modulate cell cycle
exit decisions. We have previously shown that an equilibrium
exists between CDKs and PP2A to modulate the phosphorylation
state of the three pocket proteins during the cell cycle (17). In this
equilibrium, sudden pharmacologic inhibition of CDK activity
results in immediate dephosphorylation of pocket proteins by
PP2A. Thus, cell cycle exit cues that work through accumulation
of CDK inhibitors are limited in time by the rate of accumulation
of the CKIs that stoichiometrically bind CDKs. In this scenario, a
reduction of CDK activity will require sufficient accumulation of
the upregulated CKI(s) to warrant a shift in the PP2A/CDK equi-
librium toward pocket protein dephosphorylation. Because accu-
mulation of CKIs requires protein synthesis and/or stabilization,
this process is not very fast. However, increased recruitment of
PP2A holoenzymes to pocket proteins in response to rapid signal-
ing provides a mechanism for very fast activation of particular
pocket proteins. In this study, we demonstrate that rapid FGF1
signaling promotes formation of a complex of p107 and PP2A/
B55 holoenzymes that mediate p107 dephosphorylation despite
the availability of CDK activity that maintains pRB and p130 hy-
perphosphorylation. Relative shifts in the PP2A/CDK activity ra-
tio due to selective PP2A recruitment to pocket proteins may rep-
resent a mechanistic paradigm for rapid activation of pocket
proteins. This idea is supported by the finding that oxidative stress
induces PR70, a member of the B
 family of PP2A regulatory sub-
units, resulting in rapid dephosphorylation of pRB, and perhaps
also p130/p107, in the absence of CDK inhibition (21).
This equilibrium operating in pocket proteins in which both
CDKs and PP2A are regulated is reminiscent of a similar equilib-
rium between CDK1 and PP2A/B55 holoenzymes that regulates
mitotic entry and exit (44). In vertebrates, activation of CDK1 at
the G2/M transition appears inadequate to trigger phosphoryla-
tion of CDK1 substrates in the absence of downregulation of spe-
cific PP2A holoenzymes directed to substrates by B55 and/or
B55 (45–47). As cells enter mitosis, PP2A activity drops as a
result of activation of a kinase designated MASTL/GWL, which
phosphorylates and activates direct inhibitors (ARPP19 and
ENSA) of PP2A/B55 holoenzymes (48, 49). As cells complete mi-
totic events and anaphase is triggered, CDK1 becomes inactivated
and PP2A activity increases and is required for mitotic exit (50,
51). Whether B55 is regulated via inactivation of ARPP19/ENSA
or other inhibitors in response to FGF signaling is unclear. In this
regard, we detected both ARPP19 and ENSA in B55 immuno-
precipitates via proteomics analysis. However, commercial anti-
bodies to ARPP19 and ENSA failed to detect association of these
inhibitors with B55 in RCS cells treated or untreated with FGF1
despite these proteins being detected in lysates (data not shown).
Further studies are under way to determine the mechanism that
promotes the formation of the p107-PP2A/B55 complex.
Rapid activation of p107 preceding pRB dephosphorylation.
p107/p130 double knockout mice die shortly after birth as result
of defects on endochondral bone ossification that result in short-
ened limbs and limit the size of the rib cage interfering with nor-
mal breathing (26). The bone defect is due to increased chondro-
cyte proliferation and cell density in epiphyseal centers, while
chondrocytes in the zone of flattened cells exhibit delays in cell
cycle exit and hypertrophy. These studies also showed a subtle
defect in the thickness of certain forelimb bones in p107/ mice
that was not observed in p130/ mice (26). Consistent with this
finding, p107/ chondrocytes in micromass cultures fail to exit
the cell cycle in response to FGF signaling while pRB/ chondro-
cytes exit the cell cycle as wild-type cells in this setting. Thus, early
activation of p107 appears to play a unique role in the initiation of
cell cycle exit in maturing chondrocytes. Using RCS cells, we ob-
serve that p107 is found mostly hyperphosphorylated in exponen-
tially growing cells, and hyperphosphorylated p130 is hardly de-
tectable under these conditions. Several hours after FGF
treatment, active hypophosphorylated p130 (forms 1 and 2) (39)
becomes readily visible coinciding with pRB dephosphorylation.
Since we and others have shown that hyperphosphorylated p130
(form 3) is unstable because it is targeted for proteosomal degra-
dation by the ubiquitin ligase SCFSKP2 (52, 53), inactivation of
FIG 7 Effects of B55 and/or B55 loss of function in FGF1-induced cell cycle
exit. RCS cells were transfected as described in Fig. 4D and 4 days later were
stimulated for the indicated times, collected, and processed for DNA content/
flow cytometric analysis. The percentage of cells remaining in S (A), G2/M (B),
and S	G2/M (C) phases versus untreated cells is represented at the indicated
times.
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CDKs concomitant with dephosphorylation of pRB may set the
conditions for accumulation of active hypophosphorylated p130,
which at this point may cooperate with p107 to control late events
in chondrocyte maturation and cell cycle exit. This is also consis-
tent with detecting active recruitment of p107 at the MYC pro-
moter, which has been previously shown to be downregulated
following FGF stimulation (41). Of note, although HES1 has also
been found to be potently downregulated by FGF1 (data not
shown), we found relatively low p107 occupancy following stim-
ulation by FGF1, a finding which reinforces the idea of p107 se-
lectivity and evidences the need for follow-up unbiased ChIP se-
quencing analysis to identify the key p107 regulated genes in this
process.
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